Friday Pop Quiz 7/3/2026
Which of the following wavelength and treatment settings are most appropriate for removal of the pictured lesion?
A. 1064 nm; 4 mm spot size, 110 J/cm2 fluence, and 30 ms pulse duration
B. 585 nm; 10 mm spot size, 10 J/cm2 fluence, and 20 ms pulse duration
C. 694 nm; 4 mm spot size, 3 J/cm2 fluence, and 20 ns pulse duration
D. 1064 nm; 10 mm spot size, 10 J/cm2, and 60 ms pulse dur …
Which of the following wavelength and treatment settings are most appropriate for removal of the pictured lesion?
A. 1064 nm; 4 mm spot size, 110 J/cm2 fluence, and 30 ms pulse duration
B. 585 nm; 10 mm spot size, 10 J/cm2 fluence, and 20 ms pulse duration
C. 694 nm; 4 mm spot size, 3 J/cm2 fluence, and 20 ns pulse duration
D. 1064 nm; 10 mm spot size, 10 J/cm2, and 60 ms pulse dur … 
Physician burnout is pervasive in medicine. A Stanford Medicine-led study of U.S. physicians conducted in 2023 and 2024 found nearly half experienced at least one symptom of burnout. While the broader conversation may raise burnout as a concerning issue, the lived experience of physicians tells a different story. Despite the fact burnout is so prevalent, the demands on physicians remain unchanged: … 
Post-acne scars can be disfiguring and require a creative treatment approach in patients with skin of color, according to Dr. Michelle Henry, clinical instructor of dermatology at Weill Cornell Medical College. Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Henry, who shared what energy-based devices she uses in her practice and how she chooses a device based on a p … 
Congratulations on starting dermatology residency! It’s thrilling, humbling, and yes—sometimes downright overwhelming. You’ll stretch both personally and professionally over the next year, and the lessons you learn now will shape your entire career. There are many unknowns, and it’s hard to navigate expectations. Don’t worry! I’ve been there too. Here’s some real advice that will hel … 
Lebrikizumab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that selectively targets IL-13, a key cytokine implicated in the pathogenesis of type 2 inflammatory diseases.1 Lebrikizumab binds IL-13 with high affinity and a slow dissociation rate, which prevents heterodimerization of the IL-13 receptor alpha-1 subunit (IL-13Rα1) with the IL-4 receptor alpha (IL-4Rα) signaling complex. …